(1 - 30 von 57
)
Drugmaker Roche raised prices before no-increase pledge
www.arkansasonline.com
Like a growing number of its peers, Roche Holding AG pledged recently not to raise drug prices for the rest of the year. Thing is, the Swiss company had...
Pfizer’s top dog is flyin’ high
nypost.com
... while Novo Nordisk's Lars Rebien Soerensen was the lowest-paid CEO, with $5 million, Sam Fazeli, a London-based analyst for Bloomberg ...
J&J makes big bet on rare disease with $30 billion deal
eu.northjersey.com
... hard it is to find an asset that actually makes a difference in your earnings,” said Sam Fazeli, an analyst for Bloomberg Intelligence in London.
Cambridge starts asthma drug trials | London Evening Standard
www.standard.co.uk
CAMBRIDGE Antibody Technology is starting clinical trials on a new antibody-based drug to treat severe asthma.
Novartis's $475,000 cancer breakthrough heralds new era of cures -...
www.greenwichtime.com
The Basel, Switzerland-based company is wading into a new arena of performance-based pricing, said Sam Fazeli, a Bloomberg Intelligence ...
Johnson and Johnson seals $30b Actelion deal in push for rare disease...
gulfnews.com
The deal is expensive compared to recent industry takeovers
Guardian: Smallpox vaccine on fast track | Business | The Guardian
Vaccine maker Acambis has been granted fast-track status in the United States for a weakened smallpox vaccine, which is suitable for the elderly and infirm,...
Biotech blow for Nomura
www.telegraph.co.uk
US finance house Piper Jaffray has poached two biotechnology analysts and five of the highly-regarded sales team from rival bank Nomura.
J&J hat den Actelion-Chef zum Milliardär gemacht - Handelszeitung
www.handelszeitung.ch
Damit verschlechterten sich die Aussichten auf ein Bietergefecht und eine satte Übernahmeprämie, was den Vermögenszuwachs von Clozel abschmelzen lassen könnte, sagte Sam Fazeli, Analyst bei
Sam fazeli – VietNam Breaking News
www.vietnambreakingnews.com
Bloomberg's Sam Fazeli reports on drug companies racing for an Ebola vaccine and treatment drugs. He speaks with Jonathan Ferro on Bloomberg Television's ...
Europas Börsen legen zu - Adidas- und Swatch-Aktien gefragt - WELT
www.welt.de
Die europäischen Börsen haben am Freitagmittag fester tendiert. Nach der Korrektur der Vortage stabilisierten sich die Märkte wieder.
Houses that won't find a home in a pension fund
www.telegraph.co.uk
The chancellor's last-minute decision to exclude residential property and exotica from Sipps has upset both investors and providers, report John Greenwood...
Sam Fazeli: 4 developments in cancer treatment worth celebratingwww.dailyadvent.com › news › 9222ca11a7bed
www.dailyadvent.com
Sam Fazeli: 4 developments in cancer treatment worth celebrating ... When it comes to health breakthroughs, COVID-19 vaccines have received the lion's share of ...
Mini antibodies: biotech's next big thing? - Reuters
www.reuters.com
GlaxoSmithKline Plc's head of biotech research is excited about a new generation of
sam fazeli - Opera News Kenyake.opera.news › tags › sam-fazeli
ke.opera.news
All the sam fazeli news, pictures and more, Want to know the latest updates about sam fazeli? — Click here to ke.opera.news.
UPDATE 2-Prostrakan CEO resigns on drug delays; shares fall | Reuters
www.reuters.com
* Expects to restart deliveries of anti-nausea patch in Q1
Dr Sam Fazeli joins Arecor as Non-Executive Director - BioIndustry ...www.bioindustry.org › news-listing › dr-sam-fazeli-...
www.bioindustry.org
· announce the appointment of Dr Sam Fazeli, as Non-Executive Director of the Company. Dr Fazeli is Director of EMEA Research and Senior ...
UPDATE 2-Toxicology sinks Vernalis, Biogen Parkinson's drug | Reuters
www.reuters.com
* Drug dropped after review of preclinical toxicology data
8.5 million Americans love sleeping pills: CDC - Marketplace
www.marketplace.org
A look at the modestly growing market for sleeping pills in the U.S.
Brexit could boost pharma investment and M&A -
pharmaphorum.com
Pharma companies such as GlaxoSmithKline and Johnson & Johnson have become a “Brexit Haven” as investors flee to defensive stocks.
After 190 Tries, Are We Any Closer to a Cure for Alzheimer’s? -...
www.chemdiv.com
After 190 Tries, Are We Any Closer to a Cure for Alzheimer’s?
Payback Time: How China Could Retaliate for U.S. Huawei Ban By...
www.investing.com
“The heightened U.S.-China trade war may prompt preferential treatment of domestically developed products,’’ Bloomberg Intelligence analysts Cinney Zhang and Sam Fazeli wrote in a May 23 note.
Apple and Nike brace for China’s response after Huawei ban - Los...
www.latimes.com
The move could open the door to retaliation against American companies, including the iPhone maker and shoe company but also hotel operators and others.
AstraZeneca NDA for Diabetes Combination Rebuffed by FDA
www.genengnews.com
Agency issues Complete Response Letter requesting more clinical data, a year after company cited positive Phase III results
Biogen stock jumps on positive results for Alzheimer’s drug - The...
www.bostonglobe.com
Biogen is declaring success with a treatment for Alzheimer’s disease, pointing to positive secondary results from a mid-stage study in hopes of saving a drug...
Bloomberg - Cancer Breakthrough Heralds New Era of Cures | Friends of...
friendsofcancerresearch.org
The approval of Novartis AG’s breakthrough therapy for a deadly form of leukemia opened the door to a new class of treatments even as its $475,000 price tag...
Glaxo’s Advair sees sales slip as competitors reach market
www.irishtimes.com
Leading respiratory drug faces challenges from after losing patent protection
Vaccines Alone Aren't Enough to Beat Covid-19 | Sam Fazelinewsoveraudio.com › articles › vaccines-alone-arent...
newsoveraudio.com
Vaccines Alone Aren't Enough to Beat Covid-19 | Sam Fazeli. Bloomberg. Play. Listen to the world's best audio-journalism. Try Noa today ...
FDA: AstraZeneca's diabetes drug showed increased death risk
www.inquirer.com
AstraZeneca PLC's type 2 diabetes drug Onglyza showed an increased risk of death in an analysis by U.S. regulators of a clinical trial on the heart effects of...
sortiert nach Relevanz / Datum